4tz2
From Proteopedia
(Difference between revisions)
m (Protected "4tz2" [edit=sysop:move=sysop]) |
|||
Line 1: | Line 1: | ||
- | ''' | + | ==Fragment-Based Screening of the Bromodomain of ATAD2== |
+ | <StructureSection load='4tz2' size='340' side='right' caption='[[4tz2]], [[Resolution|resolution]] 1.70Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[4tz2]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4TZ2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4TZ2 FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=39R:3-(5-PHENYL-4H-1,2,4-TRIAZOL-3-YL)ANILINE'>39R</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr> | ||
+ | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=CSO:S-HYDROXYCYSTEINE'>CSO</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4tyl|4tyl]], [[4tz8|4tz8]]</td></tr> | ||
+ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Adenosinetriphosphatase Adenosinetriphosphatase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.6.1.3 3.6.1.3] </span></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tz2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tz2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tz2 RCSB], [http://www.ebi.ac.uk/pdbsum/4tz2 PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Cellular and genetic evidence suggest that inhibition of ATAD2 could be a useful strategy to treat several types of cancer. To discover small molecule inhibitors of the bromodomain of ATAD2, we used a fragment-based approach. Fragment hits were identified using NMR spectroscopy, and ATAD2 was crystallized with three of the hits identified in the fragment screen. | ||
- | + | Fragment-based screening of the bromodomain of ATAD2.,Harner MJ, Chauder BA, Phan J, Fesik SW J Med Chem. 2014 Oct 14. PMID:25314628<ref>PMID:25314628</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | == References == | |
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Adenosinetriphosphatase]] | ||
+ | [[Category: Chauder, B A.]] | ||
+ | [[Category: Fesik, S W.]] | ||
+ | [[Category: Harner, M J.]] | ||
+ | [[Category: Phan, J.]] | ||
+ | [[Category: Atad2]] | ||
+ | [[Category: Bromodomain]] | ||
+ | [[Category: Hydrolase-hydrolase inhibitor complex]] |
Revision as of 11:15, 29 October 2014
Fragment-Based Screening of the Bromodomain of ATAD2
|